TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30669763
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose group (120 kV + FPP)
Study: 30669763
Drug: Normal dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dose group (120 kV + FBP)
Study: 26446330
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg bolus, 0.02‐0.1 mg/kg/hr infusion)
Study: 26446330
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg bolus, 1‐3 mg/kg/hr infusion)
Study: 17512147
Drug: Tablet A
Normalized name: tablet administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet A
Study: 17512147
Drug: Tablet B
Normalized name: Biaxin 4 Tablet Blister Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet B
Study: 17542016
Drug: Capsule
Normalized name: CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: 16335333
Drug: Valerian-hops combination
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian-hops combination (2 nightly tablets for 28 days, n = 59)
Study: 16335333
Drug: Diphenhydramine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (2 tablets of 25 mg for 14 days followed by placebo for 14 days, n = 60)
Study: 16335333
Drug: Valerian-hops combination
Normalized name: HOPS
DrugBank: Hops (DB10687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valerian-hops combination (n = 59)
Study: 2178660
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg and 800 mg)
Study: 2178660
Drug: Frusemide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (administered after baseline measurements)
Study: 28345790
Drug: Acyl ghrelin
Normalized name: gellan gum (low acyl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyl ghrelin infusion (1 pmol kg-1 min-1)
Study: 26444729
Drug: Daclizumab HYP
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab HYP (150 mg subcutaneously every 4 weeks)
Study: 26444729
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (30 μg intramuscularly once weekly)
Study: 19752420
Drug: 1-mg intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg intravitreal triamcinolone
Study: 19752420
Drug: 4-mg intravitreal
Normalized name: ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-mg intravitreal triamcinolone
Study: 16924272
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 3.2 g/day for 6 months
Study: 1123897
Drug: Sorbitol infusion
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol infusion at 0.125 g/kg/h
Study: 1123897
Drug: Sorbitol infusion
Normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorbitol infusion at 0.25 g/kg/h
Study: 31003654
Drug: Lavender oil
Normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender oil inhalation (1:10 ratio of lavender and sweet almond oil)
Study: 31003654
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lavender oil inhalation)
Study: 21870630
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet including 30 g day(‐1) of soy protein
Study: 16498362
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AIs) such as Anastrozole, Letrozole, and Exemestane
Study: 12175374
Drug: ITI implants
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ITI implants
Study: 3931144
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg d,l-amphetamine
Study: 24887013
Drug: Plant sterols
Normalized name: Plant Sterols/Stanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterols (2 g daily)
Study: 20624140
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Study: 20624140
Drug: Ketamine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.0 mg/kg IV followed by 0.5 mg/kg every 3 minutes as needed
Study: 17898702
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell therapy (MSCs)
Study: 9489908
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg twice daily) and Amoxicillin (750 mg three times daily)
Study: 9489908
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg twice daily) and Placebo (750 mg three times daily)
Study: 7917910
Drug: Cisplatinum (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatinum (50 mg m‐2) with ondansetron (8 mg i.v. x 3 at chemotherapy and 8 mg p.o. x 3 for 5 days)
Study: 7917910
Drug: Low or
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low or moderately emetogenic chemotherapy
Study: 31648988
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell injections (MSCs)
Study: 28514784
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (80 mg of rosuvastatin loading followed by 40 mg daily)
Study: 28514784
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy (usual-care group)
Study: 28514784
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (in patients with abnormal glucose tolerance)
Study: 28514784
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy (in patients with abnormal glucose tolerance)
Study: 25931419
Drug: Actazin high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actazin high dose (Actazin-H) [2400 mg/day]
Study: 25931419
Drug: Gold [2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold [2400 mg/day]
Study: 25931419
Drug: Actazin low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actazin low dose (Actazin-L) [600 mg/day]
Study: 23743088
Drug: TREAT decision
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TREAT decision support system for antibiotic treatment (intervention arm)
Study: 21983496
Drug: Sedative/hypnotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedative/hypnotics
Study: 28475816
Drug: Anakinra (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (recombinant human IL-1 receptor antagonist)
Study: 18206361
Drug: FSC 250/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 250/50 mcg once daily
Study: 18206361
Drug: FP 250
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FP 250 mcg once daily
Study: 18206361
Drug: FSC 100/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSC 100/50 mcg twice daily
Study: 16529615
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 500 mg bid, titrated to 1,000 mg bid
Study: 23625113
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg once daily)
Study: 9303380
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg once daily on days 16-30)
Study: 9303380
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine mesylate (300 mg every 8 hours for 30 days)
Study: 8417428
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/kg/day daily)
Study: 8417428
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 mg/kg/day divided into two doses)
Study: 3752963
Drug: AM3 (biological
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM3 (biological response modifier) with adjuvant radiotherapy and chemotherapy
Study: 3752963
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (adjuvant radiotherapy and chemotherapy without AM3)
Study: 29943350
Drug: Rivaroxaban 15
Normalized name: rivaroxaban 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor (N=696)
Study: 29943350
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT) (N=706)
Study: 29943350
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus DAPT (N=697)
Study: 25130629
Drug: Liquid nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nutritional supplement (Nutrisen) with increased whey protein (200 ml daily for 8 weeks)
Study: 25130629
Drug: Liquid nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nutritional supplement (Nutrisen)
Study: 20937162
Drug: C. longa
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. longa (6 g)
Study: 18782799
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with low-dosage Mitomycin-C (MMC) (0.2 mg/ml, 2 min application)
Study: 18782799
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with low-dosage Mitomycin-C (MMC)
Study: 18782799
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with balanced saline solution (BSS)
Study: 12528105
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (after 3 months for both groups)
Study: 10494965
Drug: New split
Approvals — FDA: no, EMA: no, PMDA: no
Description: New split influenza vaccine derived from BV-5F1 cell line
Study: 3492975
Drug: Diltiazem (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (various doses)
Study: 6415780
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg every 12 hr for five days)
Study: 6415780
Drug: Second cycle
Normalized name: 60 Second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second cycle of minocycline followed by group C polysaccharide vaccine
Study: 29907485
Drug: MCV (measles-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV (measles-containing vaccine)
Study: 29907485
Drug: MCV2 (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCV2 (second dose of measles-containing vaccine)
Study: 27631634
Drug: Epidural (EP)
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural (EP) administration of ropivacaine every 6 hours
Study: 27631634
Drug: Continuous wound
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous wound infusion (SC) of ropivacaine after a bolus dose for 48 hours
Study: 17427615
Drug: Well-equipped eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Well-equipped eye tray including fluorescein dye, materials for irrigation and foreign body removal, a short‐acting mydriatic agent, and topical anesthetics and antibiotics; prepared in advance for eye injuries.
Study: 12452939
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate (400 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Study: 12452939
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg), amoxicillin (1000 mg), metronidazole (400 mg)
Study: 7061155
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of high molecular weight proteinaceous impurities (0.1-10 micrograms of antigen) in rabbits
Study: 7061155
Drug: Repeated subcutaneous
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated subcutaneous injections of high molecular weight proteinaceous impurities in rabbits
Study: 30099602
Drug: Ciprofloxacin and
Normalized name: ciprofloxacin and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin and G-CSF
Study: 25721187
Drug: Olanzapine/Fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/Fluoxetine combination (OFC) 6/25-12/50 mg/day
Study: 25721187
Drug: Olanzapine/Fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/Fluoxetine combination (OFC)
Study: 23484632
Drug: Hydrocortisone administration
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone administration during sleep
Study: 19884625
Drug: PDE‐5 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDE‐5 inhibitors (sildenafil, vardenafil, tadalafil, mirodenafil, udenafil)
Study: 19884625
Drug: Choice of
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [MediChoice of Hydrogen Peroxide 3 10 Volume]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choice of specific PDE‐5 inhibitor
Study: 19884625
Drug: Hormonal blood
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal blood tests or hormonal treatment
Study: 17333244
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (CHO trial; 0.7 g CHO kg(‐1) h(‐1))
Study: 15496345
Drug: Muscle relaxation
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle relaxation therapy (once a week for a total of 4 times)
Study: 15496345
Drug: Ordinary daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary daily life in the reformatory (Control)
Study: 1286053
Drug: Epinephrine (1:200,000,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (1:200,000, 5 micrograms/ml)
Study: 30409776
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2 days 1 to 7 intravenously or subcutaneously with nivolumab 3 mg/kg intravenously on days 1 and 14, every 4 to 6 weeks
Study: 30409776
Drug: Azacitidine and
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine and nivolumab therapy
Study: 29737955
Drug: Barium sulfate
Normalized name: Barium Sulfate
DrugBank: Barium (DB12481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barium sulfate suspension
Study: 27036390
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg daily for 2 weeks
Study: 27036390
Drug: Ibuprofen 1200
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200 mg daily for 2 weeks
Study: 27036390
Drug: Cold compresses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold compresses 2 times daily for 2 weeks
Study: 24742662
Drug: Self-titration algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titration algorithm adjusting lispro every day (Q1D)
Study: 24742662
Drug: Self-titration algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-titration algorithm adjusting lispro every 3 days (Q3D)
Study: 24106244
Drug: Azithromycin monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin monotherapy, orally
Study: 18754834
Drug: Antidepressants given
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants given in addition to a mood stabilizer
Study: 11007104
Drug: Lactulose 30‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose 30‐60 ml/day for three months (SHE‐L)
Study: 11007104
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no lactulose, SHE‐NL)
Study: 6933705
Drug: 0.5% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% NaF solution rinsed once every 2 weeks for 3 years
Study: 6933705
Drug: 0.2% NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% NaF solution rinsed weekly
Study: 29066245
Drug: Neostigmine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.04 mg kg−1)
Study: 29066245
Drug: Edrophonium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium (0.5 mg kg−1)
Study: 24113432
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium with 300 mg iodine/ml
Study: 24113432
Drug: Contrast medium
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast medium with 370 mg iodine/ml
Study: 19222610
Drug: Ezetimibe/simvastatin 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin 10/20 mg
Study: 19758618
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid intravenously every 3 months for 4 treatments
Study: 11561564
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and metronidazole 500 mg twice daily for one week (Group A)
Study: 11561564
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus clarithromycin 250 mg and metronidazole 500 mg twice daily for one week (Group B)
Study: 11561564
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for one week (Group C)
Study: 11561564
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 250 mg twice daily for 2 weeks (Group D)
Study: 11561564
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily for 2 weeks plus amoxicillin 500 mg and clarithromycin 500 mg twice daily for 2 weeks (Group E)
Study: 7717629
Drug: Cochlear implants
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implants (Ineraid, Nucleus, or 3M/Vienna)
Study: 2197091
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for 2 weeks
Study: 2197091
Drug: Cefadroxil 1
Normalized name: CEFADROXIL 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1 g twice daily for 2 weeks
Study: 6243714
Drug: Topical ether
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ether
Study: 23602059
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (particle concentration 300 μg/m3)
Study: 17901955
Drug: FOLFIRINOX (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², bolus fluorouracil 400 mg/m², fluorouracil 46‐h continuous IV infusion 2,400 mg/m², every 2 weeks for a maximum of 12 cycles)
Study: 15753743
Drug: 6 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL/kg predicted body weight tidal volume
Study: 10845393
Drug: BCNU +
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU + 40 mg tamoxifen (group B)
Study: 10845393
Drug: BCNU +
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BCNU + 100 mg tamoxifen (group C)
Study: 1827378
Drug: Zn‐soluble combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zn‐soluble combination
Study: 31907649
Drug: Standardized physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized physical therapy group (SPTG)
Study: 27886522
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (100mg)
Study: 21293122
Drug: 1,100 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 4 weeks
Study: 21293122
Drug: 1,100 ppm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,100 ppm F (as NaF) dentifrice, brushed twice daily for 1 min for 3 weeks
Study: 16845641
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day, titrated to 90 mg/day after 1 week, then to 120 mg/day after another week, maintained for 4 weeks
Study: 16845641
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day, 90 mg/day, 120 mg/day
Study: 11099373
Drug: Caffeine 6
Normalized name: caffeine 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 6 mg á kg‐1 body mass
Study: 11099373
Drug: Caffeine 9
Normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 9 mg á kg‐1 body mass
Study: 3523711
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (BSS) in high dose (2.1 g daily)
Study: 3523711
Drug: Bismuth subsalicylate
Normalized name: Bismuth Subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bismuth subsalicylate (BSS) in low dose (1.05 g daily)
Study: 24953914
Drug: N-acetylcysteine nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine nebulized therapy
Study: 21873370
Drug: Intraoperative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative goal-directed fluid therapy (GDT) with oesophageal Doppler monitoring (ODM)
Study: 21873370
Drug: Intraoperative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative goal-directed fluid therapy (GDT)
Study: 15616893
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (15 mg per day) in addition to GC (group B)
Study: 12777950
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment adjustment
Study: 12777950
Drug: NG‐monomethyl‐l‐arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐l‐arginine